The combination of olaparib and camptothecin for effective radiosensitization
|
|
- Alyson Hancock
- 6 years ago
- Views:
Transcription
1 Miura et al. Radiation Oncology 2012, 7:62 RESEARCH Open Access The combination of olaparib and camptothecin for effective radiosensitization Katsutoshi Miura 1, Koh-ichi Sakata 1*, Masanori Someya 1, Yoshihisa Matsumoto 2, Hideki Matsumoto 3, Akihisa Takahashi 4 and Masato Hareyama 1 Abstract Background: Poly (ADP-ribose) polymerase-1 (PARP-1) is a key enzyme involved in the repair of radiation-induced single-strand DNA breaks. PARP inhibitors such as olaparib (KU , AZD-2281) enhance tumor sensitivity to radiation and to topoisomerase I inhibitors like camptothecin (CPT). Olaparib is an orally bioavailable inhibitor of PARP-1 and PARP-2 that has been tested in multiple clinical trials. The purpose of this study was to investigate the characteristics of the sensitizing effect of olaparib for radiation and CPT in order to support clinical application of this agent. Methods: DLD-1 cells (a human colorectal cancer cell line) and H1299 cells (a non-small cell lung cancer cell line) with differences of p53 gene status were used. The survival of these cells was determined by clonogenic assay after treatment with drugs and X-ray irradiation. The γh2ax focus formation assay was performed to examine the influence of olaparib on induction and repair of double-stranded DNA breaks after exposure to radiation or CPT. Results: A radiosensitizing effect of olaparib was seen even at 0.01 μm. Its radiosensitizing effect after exposure for 2 h was similar to that after 24 h. H1299 cells with depletion or mutation of p53 were more radioresistant than H1299 cells with wild-type p53. However, similar enhancement of radiosensitization by olaparib was observed with all of the tested cell lines regardless of the p53 status. Olaparib also sensitized cells to CPT. This sensitizing effect was seen at low concentrations of olaparib such as 0.01 μm, and its sensitizing effect was the same at both 0.01 μm and 1 μm. The combination of olaparib and CPT had a stronger radiosensitizing effect. The results of the γh2ax focus assay corresponded with the clonogenic assay findings. Conclusion: Olaparib enhanced sensitivity to radiation and CPT at low concentrations and after relatively short exposure times such as 2 h. The radiosensitizing effect of olaprib was not dependent on the p53 status of tumor cells. These characteristics could be advantageous for clinical radiotherapy since tumor cells may be exposed to low concentrations of olaparib and/or may have different levels of p53 mutation. The combination of olaparib and CPT had a stronger radiosensitizing effect, indicating that combining a PARP inihibitor with a topoiomerase I inhibitor could be promising for clinical radiosensitization. Keywords: PARP inihibitor, Olaparib, Camptothecin, Topoisomerase I inhibitor, Radiosensitization Background DNA is the principal target for the biologic effects of radiation. For radiotherapy, this comprises single strand breaks (SSB) and double-strand breaks (DSB) [1]. SSB are not directly cytotoxic but during DNA replication may generate potentially lethal DSB by collapse of stalled replication forks * Correspondence: sakatako@sapmed.ac.jp 1 Department of Radiology, Sapporo Medical University, School of Medicine, S1W16, Chuo-Ku, Sapporo , Japan Full list of author information is available at the end of the article [2]. Radiation-induced SSB are primarily repaired by base excision repair [3], of which poly (ADP-ribose) polymerase- 1 (PARP-1) is a key component. PARP-1 binds to SSB, activating poly ADP-ribosylation of itself and other proteins, triggering recruitment of repair factors and release of PARP-1 from the damaged site [4]. PARP inhibitors inhibit SSB repair and the unrepaired SSB generate collapsed replication forks which give rise to potentially lethal DSB, leading to radiosensitization [5]. Topoisomerase I poisons such as camptothecin (CPT) exert their cytotoxic effects by 2012 Miura et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
2 Miura et al. Radiation Oncology 2012, 7:62 Page 2 of 9 binding to and stabilizing the DNA helicase enzyme topoisomerase I. This enzyme plays a vital role in facilitating unwinding of the DNA double helix during DNA replication to relieve torsional strain. The mechanism involves temporary insertion of DNA breaks to allow unwinding, and an intermediate DNA/protein structure termed the cleavable complex is generated. Topoisomerase I poisons stabilize the cleavable complex and extend the lifetime of the associated DNA strand breaks. PARP-1 is involved in the resolution of these DNA breaks, so inhibition of PARP activity increases the yield of unrepaired DNA damage and consequent cell death [6]. Olaparib (KU , AZD-2281) is an orally bioavailable inhibitor of PARP-1 and PARP-2 and a phase 1 trial using olaparib has been reported [7]. The purpose of this study was to examine characteristics of sensitizing effects of olaparib to radiation and a topoisomerase I inhibitor, CPT for clinical application of olaparib. We found that olaparib sensitized cells to radiation and also CPT, even at low concentrations such as 0.01 μm. The radiosensitizing effect of olaparib at exposure for 2 h was similar as for 24 h. These characteristics can be advantageous in radiotherapy since tumor cells may have low concentrations of olaparib due to the limited ability of drugs to penetrate tumor tissue. We also examined the radiosensitizing effects of the combined use of olaparib and CPT. Methods [Drugs, cells and cell culture] Olaparib was obtained from JS Research Chemicals Trading (Germany). CPT was obtained from Sigma Chemical Company. DLD-1 is a human colorectal carcinoma cell line. H1299 is a p53-null non-small lung carcinoma cell line. H1299 cells were transfected with pcmv-bam-neo vector (neo) alone (as a control) and with wild-type p53 (wt) or mutated p53 gene [8,9]. H1299/mp143 (m143), H1299/mp175 (m175), and H1299/mp248 (m248) were made with transfection of mutated p53 gene into codon 143, 175, 248 of H1299 cells, respectively. To determine whether p53 mrna and the protein were stably expressed in these transfectants, we analyzed the reverse transcriptase-polymerase chain reaction restriction fragment length polymorphism on the sequence of transfected codon of the p53 gene for the mrna. We also performed Western blot analysis for the protein. H1299 (wt, m248, m175, m143, neo) cells were cultured in MEM medium supplemented with 10% fetal calf serum. DLD-1 was cultured in RPMI-1640 medium supplemented with 10% fetal calf serum. All these cell lines were cultured at 37 C. [Cell culture and clonogenic assay] The survival of these cells after various treatments such as drug treatment and X-ray irradiation was determined as their colony-forming ability. The time between plating cells and treatments such as radiation and/or drug exposure was 24 h. Experiments were repeated three times. Mean values and standard error of the mean were expressed. We tested the significance at the p < 0.05 for our observations. The X-ray dose-survival curves were fitted to the linear quadratic equation, survival fraction = exp ( αd-βd 2 ), where D is the X-ray dose. D 37, the X-ray dose giving 37% survival was calculated from the fitted linear quadratic equation. Enhancement ratio was calculated as the D 37 of untreated cells divided by that of treated cells. Since CPT have the cell killing effects, we excluded their cell killing effects in the calculation of enhancement ratio. We made the hypothetical survival curve in which the value of survival fraction was 1 at 0 Gy in the combined treatment of CPT and radiation. [γh2ax focus assay] Mouse monoclonal anti-γh2ax (Upstate, NY, USA) antibody and rabbit polyclonal anti- Rad51 (Oncogene, CA, USA) antibody were used. DLD-1 cells were exposed to olaparib (1 μm) for 8 h and/or CPT (0.01 μm) for 6 h. Since CPT has the cell killing effect, we used the shorter exposure time in CPT than olaparib. When cells were irradiated, 4 Gy of radiation was performed after 4 h exposure of olaparib and/or 2 h exposure of CPT. Then, cells were applied on slide glass at 24 h after irradiation. Cells diluted to appropriate numbers were grown on a glass slide and fixed with cold methanol for 20 min, rinsed with cold acetone for 10 seconds, and then air-dried. Above mentioned antibodies to γh2ax or Rad51 were used as the primary antibody. Alexa-546-conjugated antimouse IgG (Molecular Probes) were used for visualization of γh2ax and Rad51. Slides were mounted with antifade reagent (Mounting medium, DAKO). Foci were observed with an Olympus fluorescent microscope under oil immersion. For quantification of foci, clear and easily distinguished dots of certain brightness were counted as positive foci. The number of foci was counted in 100 cells of sample each time point by visual inspection and average number of foci per cell was calculated. Cells that had 5 or more of Rad51 were considered as Rad51 positive. [Flowcytometry] For estimation of the distribution of cells in different phases of the cell cycle, FACS-analysis of cells stained with propidium iodide (PI) was performed. Harvested cells were fixed in 70% of ethanol and stored at 4 C until analysis. Fixed cells were washed once in PBS, incubated with PBS supplemented with RNase A (0.25 mg/ml) for 30 min at 37 C and stained in a PI-containing solution (50 μg PI/ml in PBS)for 10 min at 4 C. The cells were analyzed on a flowcytometer (FACS Calibur, Becton Dickinson, USA).
3 Miura et al. Radiation Oncology 2012, 7:62 Page 3 of 9 Results [Radiosensitizing effect of olaparib at various exposure times and concentrations] Figure 1a demonstrates the relationship between the concentration of olaparib and its radiosensitizing effect. The surviving fraction was significantly reduced after exposure to 0.01 μm olaparib (p < 0.05) compared with the control (radiation alone), indicating that this agent had a radiosensitizing effect even at low concentrations. The radiosensitizing effect increased in a concentration-dependent manner. Figure 1b demonstrates the relationship between the exposure time and the radiosensitizing effect of olaparib. A radiosensitizing effect was seen after only 2 h of exposure, and it was similar to the effect after 24 h of exposure. Additional file 1 shows the relationship between the olaparib concentration and its radiosensitizing effect on DLD-1 cells. These cells were treated with 4 Gy of radiation and were exposed to various concentrations of olaparib for 1 h before irradiation and 24 h after irradiation. Additional file 2 shows the relationship between the olaparib exposure time and its radiosensitizing effect on Figure 1 a. The relationship between concentrations of olaparib and radiosensitizing effects. DLD-1 cells were treated with various concentrations of olaparib for 1 h before radiation and 24 h after radiation. b. The relationship between exposure time (1 h or 24 h) of olaparib and radiosensitizing effects. DLD-1 cells were treated with 1 μm of olaparib for 1 h before radiation and 1 h or 23 h after radiation. c. Clonogenic cell survival assay of H1299 cells with various status of p53 gene. m143, m175, and m248 were made with transfection of mutated p53 gene into codon 143, 175, 248 of H1299 cells, respectively. Control : treated with radiation alone; Olaparib (+) :treated with radiation and olaparib. Cells were treated with 1 μm of olaparib for 1 h before radiation and 2 h after radiation.
4 Miura et al. Radiation Oncology 2012, 7:62 Page 4 of 9 DLD-1 cells. The results displayed in Additional file 1 and Additional file 2 correspond with those shown in Figure 1a and 1b. Cells were treated with 4 Gy of radiation and were exposed to 1 μm olaparib for 1 h before irradiation and various times after irradiation. In these experiments, a radiation dose of 4 Gy was used since it killed more cells than 2 Gy, and the difference between various treatments was clearer at 4 Gy. Olaparib did not decrease plating efficiency at any of the exposure times or concentrations examined in this study. [Radiosensitizing effect of olaparib on human cancer cells with different p53 statuses] We examined whether the p53 status of tumor cells influenced the enhancement of radiosensitivity by olaparib. To assess the influence of p53 status, we used five human lung cancer cell lines with identical genotypes except for p53 (wt, m143, m175, m248, and neo) and found that wt cells were significantly more radiosensitive than m143 and neo cells (p < 0.01). Conversely, m143 cells were significantly more radioresistant than m248 and wt cells (p < 0.01). These results indicated that the p53 status influenced the radiosensitivity of H1299 cell lines. Olaparib enhanced the radiosensitivity of all tumor cell lines examined, especially at higher radiation doses (Figure 1c). Table 1 shows the values of α and β in the linear quadratic equation for calculating the surviving fraction, i.e., surviving fraction = exp ( αd-βd 2 ). Similar enhancement of radiosensitization was observed with all cell lines tested regardless of the p53 status. Exposure to olaparib alone (1 μm, 3 h) did not affect the plating efficiency of any cell line examined in this study. [Sensitization to CPT by olaparib] In order to examine the influence of olaparib on the sensitivity of DLD-1 cells to the topoisomerase I inhibitor CPT, we performed a clonogenic cell survival assay. Figure 2a Table 1 Radiation enhancement ratio by olaparib α β enhancement ratio wt Control 0.27 ± ± Olaparib(+) 0.28 ± ±0.002 neo Control 0.19 ± ± Olaparib(+) 0.22 ± ±0.008 m143 Control 0.11 ± ± Olaparib(+) 0.13 ± ±0.009 m175 Control 0.22 ± ± Olaparib(+) 0.29 ± ±0.012 m248 Control 0.21 ± ± Olaparib(+) 0.26 ± ±0.005 demonstrates that olaparib sensitized the cells to CPT. This effect was seen even at low concentrations of CPT, such as μm, and it was maximal around 0.01 or μm. We also examined the influence of the concentration of olaparib on its sensitizing effect, especially in regard to low concentrations (Figure 2b). A sensitizing effect was evident at only 0.01 μm and the strength of the sensitizing effect was the same at both 0.05 μm and1μm. [Radiosensitization with olaparib plus CPT] Figure 3a shows the surviving fraction of DLD-1 cells after irradiation combined with exposure to olaparib and/or CPT. Since CPT had a cytotoxic effect, the surviving fraction was less than 1 at 0 Gy. Compared with radiation alone, radiation combined with olaparib or CPT significantly reduced the surviving fraction of DLD- 1 cells (p < 0.01). The greatest reduction of the surviving fraction was achieved by the combination of 1 μm of olaparib and CPT (p < 0.001). As shown in Figure 3b, the surviving fraction of cells exposed to CPT at 0 Gy of irradiation has been adjusted to 1. It can be seen that the combination of olaparib and CPT had the strongest effect since olaparib increased sensitivity to both radiation and CPT. The enhancement ratio (D 37 ) for 0.1 μm olaparib and CPT was 1.37, while that for 1 μm olaparib and CPT was In addition, the enhancement ratio (D 37 ) for 1 μm olaparib alone was 1.20 and that for CPT alone was [γh2ax focus formation assay after irradiation or CPT] In order to examine the relationship between olaparibinduced sensitization to radiation or CPT and the induction of double-stranded DNA breaks (DSB), we counted residual γh2ax foci at 24 h after irradiation and 20 h after treatment with olaparib and/or CPT (Figure 4). We also analyzed γh2ax foci in relation to the existence of Rad51 foci. Induction of Rad51 by irradiation is cellcycle dependent, since it is preferentially formed in the S and G2/M phases [10]. Thus, the results of the γh2ax focus assay can be evaluated by taking into consideration the influence of the cell cycle. Figure 4a shows the γh2ax and Rad51 foci in untreated DLD-1 cells, cells treated with irradiation (IR), and cells treated with CPT. Figure 4b presents the results for cells with Rad51 foci. There was no significant difference between the control cells (Ola-, CPT-, IR-) and cells treated with olaparib (Ola+, CPT-, IR-), suggesting that olaparib alone did not induce DSB. Cells treated with radiation (Ola-, CPT-, IR+) had significantly more foci than control cells (Ola-, CPT-, IR-) as did cells treated with CPT (Ola-, CPT+, IR-), indicating that radiation or CPT induced DSB. Cells exposed to radiation combined with
5 Miura et al. Radiation Oncology 2012, 7:62 Page 5 of 9 Figure 2 a. The effect of olaparib on CPT toxicity. DLD-1 cells were treated with 1 μm of olaparib and various cocentrations of CPT for 6 h. Values shown are the mean ± standard error of the mean. b. The relationship between concentrations of olaparib and sensitizing effects to CPT in DLD-1 cells. Cells were treated with 0.01 μm of CPT and various concentrations of olaparib for 6 h. Values shown are the mean ± standard error of the mean. olaparib (Ola+, CPT-, IR+) had significantly more foci than cells treated with radiation alone (Ola-, CPT-, IR+). In addition, cells exposed to CPT combined with olaparib (Ola+, CPT+, IR-) showed significantly more foci than cells treated with CPT alone (Ola-, CPT+, IR-), revealing that olaparib enhanced the induction of DSB by radiation or CPT. Cells exposed to radiation combined with olaparib (Ola+, CPT-, IR+) had a similar number of foci as cells exposed to radiation combined with CPT (Ola-, CPT+, IR+), showing that olaparib and CPT caused similar enhancement of the induction of DSB by radiation. Cells exposed to radiation combined with olaparib and CPT (Ola+, CPT+, IR+) had the most foci among all of the treatment groups. Figure 4c presents the results for cells without Rad51 foci. The findings are similar to those shown in Figure 4b. However, the enhancement of radiation-induced DSB by olaparib and/or CPT was less marked in cells without Rad51 foci than in cells with Rad51 foci. There was no significant difference between radiation combined with olaparib (Ola+, CPT-, IR+) and radiation alone (Ola-, CPT-, IR+) in cells without Rad51 foci. [Effects of olaparib, CPT and radiation on the cell cycle] Figure 4d shows the cell cycle after the same treatments as Figure 4b and c. There was no difference between the control cells (Ola-, CPT-, IR-) and cells treated with olaparib (Ola+, CPT-, IR-), indicating
6 Miura et al. Radiation Oncology 2012, 7:62 Page 6 of 9 Figure 3 a. Cell survivals with radiation combined with olaparib and/or CPT. DLD-1 cells were treated with 0.1 or 1 μm of olaparib and/or 0.01 μm of CPT for 4 h before irradiation and for 2 h after radiation. b. Radiosensitization with olaparib and/or CPT. Figure 3b was made by modifying Figure 3a. The survival fraction of CPT at 0 Gy in Figure 3a was corrected to 1. that olaparib alone did not change cell cycle distributions. Cells treated with radiation (Ola-, CPT-, IR+) or CPT (Ola-, CPT+, IR-) tended to have more S phase cells than the control cells (Ola-, CPT-, IR-). Radiation and olaparib (Ola+, CPT-, IR+) had the similar cell cycle distribution to radiation alone (Ola-, CPT-, IR+). In contrast, cells treated with CPT and olaparib (Ola+, CPT+, IR-) tended to have reduced S phase cells, compared with CPT alone (Ola-, CPT+, IR-). Cells treated with olaparib, CPT and radiation (Ola+, CPT+, IR+) had increased G2/M phase cells and reduced S phase cells, compared with the other treatments. Discussion PARP inhibitors such as olaparib increase sensitivity to radiation and to topoisomerase I inhibitors such as CPT [4]. The concentration of olaparib tested in previous studies was 0.5 or 1 μm [5,11]. In a clinical study, the plasma concentration of olaparib reached 11.5 μm (5 μg/ml) after oral administration of 100 or 200 mg, which are doses that do not cause dose-limiting toxicity [7]. The present findings support the clinical usefulness of olaparib at oral doses of 100 to 200 mg. However, the ability of drugs to penetrate tumor tissue in vivo is often limited, so that some tumor cells may not be exposed
7 Miura et al. Radiation Oncology 2012, 7:62 Page 7 of 9 Figure 4 γh2ax foci at 24 hours after irradiation and cell cycle distribution. DLD-1 cells were treated with 4 Gy of radiation and/or 1 μm of olaparib for 8 h and/or 10nM of CPT for 6 h. (a) Foci of γh2ax and Rad51 in DLD-1 cells treated with various combinations of olaparib, CPT, or irradiation (IR). DAPI(4',6-diamidino-2-phenylindole) was used to stain nucleus. Ola(+): with olaparib. IR( ): without irradiation. (b) Results of cells that were positive for Rad51 foci. (c) Results of cells that were negative for Rad51 foci. (d) Cell cycle distributions. to effective concentrations [12]. Therefore, it is possible that tumor cells may be exposed to much lower olaparib concentrations than 0.5 or 1 μm. For this reason, we examined the sensitizing effect of olaparib for radiation and CPT at very low concentrations. Figure 1a demonstrates the relationship between the olaparib concentration and its radiosensitizing effect on DLD-1 cells. Although the radiosensitizing effect of olaparib showed a concentration-dependent increase, low concentrations (such as 0.01 μm) still had a radiosensitizing effect, indicating that effective radiosensitization achieved even for tumor cells exposed to low concentrations of this agent. We also examined the relationship between the exposure time and the radiosensitizing effect of olaparib. Figure 1b demonstrates that the radiosensitizing effect of olaparib after exposure for 2 h was similar to that at 24 h, demonstrating that effective radiosensitization could be achieved even for tumor cells with a short exposure time. Olaparib enhances radiosensitivity by inhibiting the repair of SSB. Unrepaired SSB lead to collapse of replication forks that give rise to potentially lethal DSB, leading to radiosensitization [5]. Thus, SSB are converted to DSB during replication after exposure to olaparib [13]. Longer incubation times than 2 h after irradiation might be required to convert SSB to DSB since the cell cycle of
8 Miura et al. Radiation Oncology 2012, 7:62 Page 8 of 9 DLD1 cells lasts for 24 h or longer. However, we found that 2 h of incubation with olaparib after irradiation is sufficient for radiosensitization and that exposure to this agent throughout the entire period of SSB repair is not necessary to enhance the generation of DSB. In order to test the potential clinical value of olaparib, we also examined whether the p53 status of tumor cells influenced the enhancement of radiosensitization using five human lung cancer cell lines with identical genotypes except for p53 (wt, m143, m175, m248, and neo). We found that H1299 cells with depletion or mutation of p53 were more radioresistant than H1299 cells with wild-type p53, showing that p53 status influenced the radiosensitivity of these cell lines. There have been conflicting reports concerning the relationship between p53 status and radiosensitivity. Some authors have reported that p53 gene mutation decreases radiosensitivity [14], while others have reported an increase of radiosensitivity [15] or no correlation with radiosensitivity [16]. Because p53 regulates multiple aspects of the cell cycle, DNA repair, and apoptosis after irradiation [17], this protein not only determines cell death but also cell survival. Accordingly, cells with various p53 statuses could be more radiosensitive or radioresistant [18]. In the present study, the surviving fraction was reduced by exposure to olaparib for all of the cell lines tested with various p53 statuses. Enhancement of radiosensitization was similar for all of the cell lines regardless of p53 status (Table 1), indicating that the radiosensitizing effect of olaparib is independent of p53. Next, we investigated the effect of olaparib on sensitivity to CPT. Figure 2a shows the relationship between the olaparib concentration and its CPT-sensitizing effect. Olaparib sensitized cells to the cytotoxic effect of CPT, even at a CPT concentration of only μm. The combination of olaparib with CPT significantly reduced the surviving fraction over the range of CPT concentrations from to 0.02 μm. We also examined the relationship between the sensitizing effect of olaparib and its concentration, especially at low concentrations (Figure 2b). A sensitizing effect was still apparent at a concentration of 0.01 μm and the effect seen at this level was similar to that obtained at 1 μm. We then investigated the combined effects of olaparib, CPT, and radiation. Figure 3a displays the surviving fraction of DLD-1 cells after treatment with olaparib and/or CPT. The combination of radiation with olaparib or CPT significantly increased the lethal effect of radiation (p < 0.01), except when olaparib was combined with 2 Gy. The cytotoxic effect of olaparib, CPT, and radiation all together was much greater than that of radiation alone. In order to compare the radiosensitizing effect of CPT with that of olaparib, we adjusted the surviving fraction at 0 Gy to 1 in Figure 3b, since CPT itself had a cytotoxic effect. Then we assessed the radiosensitivity of DLD-1 cells after treatment with olaparib or CPT. The radiosensitizing effect of 1 μm olaparibwassimilartothat of CPT at 4 Gy and greater than that of CPT at 6 and 8 Gy (p < 0.01). Since olaparib increased sensitivity to both radiation and CPT, the combination of olaparib and CPT had the strongest radiosensitizing effect. The enhancement ratio (D 37 ) of olaparib plus CPT was larger than that for either olaparib alone or CPT alone. Thus, combination therapy with PARP inhibitors and topoisomerase I inhibitors may be a promising strategy for enhancing the effects of radiotherapy. After DSB are induced by irradiation or cytotoxic drugs, H2AX is rapidly phosphorylated and there is always a constant number or percentage of γh2ax formed per DSB. Therefore, γh2ax is a sensitive and early indicator of DSB in vitro and in vivo [19].Furthermore,residualγH2AX at 24 h after irradiation can be used to assess the radiosensitivity of cells or their ability to recover from damage and the efficiency of the cellular repair process [20]. Accordingly, we investigated residual γh2ax foci after exposure of cells to radiation, olaparib, and CPT. Olaparib alone did not increase γh2ax foci, while radiation or CPT did so. Radiation combined with olaparib and CPT produced the most foci among all of the treatment groups. These findings agreed with the results of clonogenic assays, suggesting that the sensitizing effect of olaparib for radiation or CPT is related to induction of DSB or to inhibiting the repair of DSB. We also used radiation-induced Rad51 foci to investigate the cell cycle dependence of γh2ax focus formation after various treatments. We found that enhancement of radiation-induced DSB by olaparib and CPT was greater in cells with Rad51 foci than in cells without Rad51 foci, indicating that olaparib had a stronger effect on the induction of DSB by radiation or CPT in the S and G2/M phases than in the G1 phase. Figure 4d shows the cell cycle after the treatments with olaparib, CPT, or radiation. Olaparib alone did not change cell cycle distributions. Cells treated with radiation or CPT had more S phase cells than the control cells, corresponding to that radiation [21] or CPT [22] arrests or delays cell cycle progression during the S phase. Cells treated with CPT and olaparib had less S phase cells than CPT alone. This might suggest that olaparib enhances the S phase specific cell killing effect of CPT [23]. The combination of olaparib, CPT and radiation reduced S phase and increased G2/M phase. This effect might result from S phase specific cell killing with CPT and G2/M arrest with radiation. Conclusion Olaparib enhanced the sensitivity of radiation and CPT, even at low concentrations, such as 0.01 μm. The radiosensitizing effects of olaparib at exposure for 2 h had the
9 Miura et al. Radiation Oncology 2012, 7:62 Page 9 of 9 similar as for 24 h. The radiosensitizing effect of olaprib did not depend on p53 status. These characteristics can be advantageous in clinical radiotherapy since tumor cells may have low concentrations of olaparib and/or p53 mutation. The combination of olaparib and CPT had the good radiosensitizing effects, indicating that the combination of PARP inhibitor and topoiomerase I inhibitor can be promising as a method of clinical radiosensitization. Additional files Additional file 1: The relationship between concentrations of olaparib and radiosensitizing effects. DLD-1 cells were treated with 4 Gy of radiation and various concentrations of olaparib for 1 h before radiation and 24 h after radiation. Additional file 2: The relationship between exposure time of olaparib and radiosensitizing effects. DLD-1 cells were treated with 4 Gy of radiation and 1 μm of olaparib for 1 h before radiation and various times after radiation. Competing interest The authors declare that they have no competing interests. Authors contributions KM performed experiments and drafted the manuscript. KS conceived of the study and drafted the manuscript. MS performed γ-h2ax assay. YM participated importantly in the conception of the study and helped to draft the manuscript. HM and AT made H1299 cells with various p53 status and analyzed these characteristics of cells. MH participated importantly in the conception and design and helped to draft the manuscript. All authors read and approved the final manuscript. Acknowledgments The research were supported in part by a Grant-in Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan and by a grant from program for developing the supporting system for upgrading the education and research in Sapporo Medical University. Author details 1 Department of Radiology, Sapporo Medical University, School of Medicine, S1W16, Chuo-Ku, Sapporo , Japan. 2 Tokyo Institute of Technology, Research Laboratory for Nuclear Reactors, N Ookayama, Meguroku, Tokyo , Japan. 3 Department of Oncology, Biomedical Imaging Research Center, University of Fukui, Eiheiji-cho, Fukui , Japan. 4 Advanced Scientific Research Leaders Development Unit, Gunma University, Showa-machi, Maebashi, Gunma , Japan. Received: 17 October 2011 Accepted: 2 April 2012 Published: 23 April 2012 References 1. Hall EJ: DNA strand breaks and chromosomal aberrations. In Radiobiology for the radiologist, ed. 6th edition. Edited by Hall EJ, Giaccia AM. Philadelphia: Lippincott Williams & Wilkins; 2006: Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel T, Helleday T: Spontaneous homologous recombination is induced by collapsed replication forks that are caused by ebdogenous DNA single-strand breaks. Mol Cell Biol 2005, 25(16): Caldecott KW: Protein-protein inetractions during mammalian DNA single-strand break repair. Biochem Soc Trans 2003, 31: Chalmers AJ: The potential role and application of PARP inhibitors in cancer treatment. Brit Med Bull 2009, 89: Dungey FA, Loser DA, Chalmers AJ: Replication-dependent radiosensitization of human glioma cells by inhibition of poly (ADP-ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008, 72(4): Smith LM, Willmore E, Austin CA, Curtin NJ: The novel poly (ADP-ribose) polymerase inhibitor, AG14361, sensitizes celss to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 2005, 11(23): Fong PC, Boss DS, Timothy A, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JHM, de Bono JS: inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2): Jin Z-H, Matsumoto H, Hayashi S, Hatashita M, Ohtsubo T, Shioura H, Kitai R, Kano E: p53-independent thermosensitization by mitomycin c in human non-small-cell cancer cells. Int J Radiat Oncol Biol Phys 2004, 59: KawashimaD,SogaM,TakeuchiR,MatsumotoH,OhtsukaK: Molecular caperone inducers facilitate the functional restoration of temperature-sensitive mutant p53 protein. Thermal Med 2010, 26: Yuan SF, Chang H, Lee EY: Ionizing radiation-induced Rad51 nuclear focus formation is cell cycle-regulated and defective in both ATM - / - and c-abl - / - cells. Mutat Res 2003, 525: Loser DA, Shibata A, Shibata AK, Woodbine LJ, Jeggo PA, Chalmers AJ: Sensitization to radiation and alkylating agents by inhibitors of poly (ADP-ribose) polymerase is enhanced incells deficient in DNA double-strand break repair. Mol Cacncer ther 2010, 9(6): Tredan O, Galmarini CM, Patel K, Tannock IF: Drug resistamce and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99: Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434: Sinclair WK: The combined effects of hydroxyurea and x-rays on Chinese hamster cells in vitro. Cancer Res 1968, 28: Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR: p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993, 53(16): Slichenmyer WJ, Nelson WG, Slebos RJ, Kastan MB: Loss of a p53- associated G1 checkpoint does not decrease cell survival following DNA damage. Cancer Res 1993, 53(18): Hall EJ: Repair of radiation damage and the dose-rate effect. In Radiobiology for the radiologist, ed. 6th edition. Edited by Hall EJ, Giaccia AM. Philadelphia: Lippincott Williams & Wilkins; 2006: Takahashi A, Matsumoto H, Yuki K, Yasumoto J, Kajiwara A, Aoki M, Furusawa Y, Ohnishi K, Ohnishi T: High-LET radiation enhanced apoptosis but not necrosis regardless of p53 status. Int J Radiat Oncol Biol Phys 2004, 60(2): Rogakou EP, Nieves-Neira W, Boon C, Pommier Y, Bonner WM: Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139. J Biol Chem 2000, 275: Klokov D, MacPhail SM, Banath JP, Byrne JP, Olove PL: Phosphorylated histone H2AX in trlation to cell survival in tumor cells and xenografts exposed to single and fractionated doses of X-rays. Radiother Oncol 2006, 80: Guo CY, D Anna JA, Larner JM: The radiation-induced S-phase checkpoint is independent of CDKN1A. Radiat Res 1999, 151: Shao R-G, Cao C-X, Shimizu T, O Connor PM, Kohn KW, Pommier Y: Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997, 57: Hsiang Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 1989, 49: doi: / x-7-62 Cite this article as: Miura et al.: The combination of olaparib and camptothecin for effective radiosensitization. Radiation Oncology :62.
The Need for a PARP in vivo Pharmacodynamic Assay
The Need for a PARP in vivo Pharmacodynamic Assay Jay George, Ph.D. Chief Scientific Officer Trevigen, Inc. Gaithersburg, MD Poly(ADP-ribose) polymerases are promising therapeutic targets. In response
More informationSupplementary Figure 1
Supplementary Figure 1 a γ-h2ax MDC1 RNF8 FK2 BRCA1 U2OS Cells sgrna-1 ** 60 sgrna 40 20 0 % positive Cells (>5 foci per cell) b ** 80 sgrna sgrna γ-h2ax MDC1 γ-h2ax RNF8 FK2 MDC1 BRCA1 RNF8 FK2 BRCA1
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose)
More informationTumor cell reassortment within the cell cycle (including checkpoints and cell-cycle arrest)
Tumor cell reassortment within the cell cycle (including checkpoints and cell-cycle arrest) Carsten Herskind Dept. of Radiation Oncology. Universitätsmedizin Mannheim Medical Faculty Mannheim, Heidelberg
More informationPRINCIPAL INVESTIGATOR: Robert L. Nussbaum, MD. CONTRACTING ORGANIZATION: University of California San Francisco San Francisco, CA 94103
Award Number: W81XWH-12-1-0569 TITLE: Functional Analysis of Variants of Unknown Significance in BRCA1 and BRCA2 Using Complementation of a Synthetic Lethal Interaction with PARP Inhibition PRINCIPAL INVESTIGATOR:
More informationModelling of Biological Processes
Modelling of Biological Processes WHAT HAPPENS AFTER EARLY MOLECULAR DAMAGE? Stephen McMahon Queen s University, Belfast, Northern Ireland 3 rd August 2016 1 Do we need biology? The Linear-quadratic relationship
More informationCellular Stress Response Induced by Low Dose Gamma Radiation
Proceedings of the Pakistan Academy of Sciences 51 (2): 139 144 (2014) Pakistan Academy of Sciences Copyright Pakistan Academy of Sciences ISSN: 0377-2969 (print), 2306-1448 (online) Research Article Cellular
More informationRadiobiology of fractionated treatments: the classical approach and the 4 Rs. Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica
Radiobiology of fractionated treatments: the classical approach and the 4 Rs Vischioni Barbara MD, PhD Centro Nazionale Adroterapia Oncologica Radiobiology It is fundamental in radiation oncology Radiobiology
More informationEx vivo functional assays for Homologous Recombination deficiency in breast cancer. Dik C. van Gent
Ex vivo functional assays for Homologous Recombination deficiency in breast cancer Dik C. van Gent Breast cancer types treatments ER/PR: anti-hormonal therapy HER2: Herceptin Triple negative (TNBC): no
More informationFactors determining DNA double strand break repair pathway choice in G2 phase.
Supplementary Data Factors determining DN double strand break repair pathway choice in G2 phase. tsushi Shibata 1, Sandro Conrad 2, Julie irraux 1, Verena Geuting 2, Olivia arton 2, mani Ismail 1, ndreas
More informationDNA repair and synthetic lethality
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2011 DNA repair and synthetic lethality Gong-she Guo Shandong University Feng-mei Zhang Shandong University Rui-jie
More informationBrian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology
Brian T Burgess, DO, PhD, GYN Oncology Fellow Rachel W. Miller, MD, GYN Oncology Epithelial Ovarian Cancer - Standard Current Treatment: Surgery with De-bulking + Platinum-Taxane based Chemotherapy - No
More informationSupplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation.
Supplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation. (a) Embryonic fibroblasts isolated from wildtype (WT), BRAF -/-, or CRAF -/- mice were irradiated (6 Gy) and DNA damage
More informationEvaluation of DNA damage induced by proton and lithium beams in murine melanoma cells
Evaluation of DNA damage induced by proton and lithium beams in murine melanoma cells IL Ibañez *1,2, C Bracalente 1, M Edreira 1, MA Palmieri 3, B Molinari 1,2, L Policastro 1,2, A Kreiner 1,2,4, A Burlón
More informationCHAPTER TWO MECHANISMS OF RADIATION EFFECTS
10-2 densely ionizing radiation CHAPTER TWO MECHANISMS OF RADIATION EFFECTS 2.0 INTRODUCTION Cell survival curves describe the relationship between the fractional survival, S, of a population of radiated
More informationUNC-Duke Biology Course for Residents Fall
UNC-Duke Biology Course for Residents Fall 2018 1 UNC-Duke Biology Course for Residents Fall 2018 2 UNC-Duke Biology Course for Residents Fall 2018 3 UNC-Duke Biology Course for Residents Fall 2018 4 UNC-Duke
More informationSUPPLEMENTAL FIGURE LEGENDS
SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure S1: Endogenous interaction between RNF2 and H2AX: Whole cell extracts from 293T were subjected to immunoprecipitation with anti-rnf2 or anti-γ-h2ax antibodies
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AWARD NUMBER: W81XWH-13-1-0484 TITLE: PRINCIPAL INVESTIGATOR: Elizabeth Swisher CONTRACTING ORGANIZATION: University of Washington REPORT DATE: 2014 TYPE OF REPORT: Annual Report PREPARED FOR: U.S. Army
More informationTFY4315 STRÅLINGSBIOFYSIKK
Norges teknisk-naturvitenskaplige universitet Institutt for fysikk EKSAMENSOPPGÅVER med løysingsforslag Examination papers with solution proposals TFY4315 STRÅLINGSBIOFYSIKK Biophysics of Ionizing Radiation
More informationDNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations. Peter de Boer
DNA double-strand break repair of parental chromatin in ooplasm and origin of de novo mutations Peter de Boer Department of Obst.& Gynaecology, Div. Reproductive Medicine Radboud University Nijmegen Medical
More informationPARP inhibitors for breast cancer
PARP inhibitors for breast cancer Mark Robson, MD Memorial Sloan Kettering Cancer Center Agenda Mechanism of action Clinical studies Resistance mechanisms Future directions Poly (ADP-ribose) Polymerases
More informationFigure S1. B % of Phosphorylation 32H. 32ss
Figure S1 8H 32ss 32H 32Hc % of Phosphorylation 3 32H 2 1 32ss 1 2 3 4 Extract (μg) C % of Phosphorylation 18 12 6-32H 32Hc 8H 32ss Dbait Figure S1. List of the Dbait molecules and activation of DN-PK
More informationLET, RBE and Damage to DNA
LET, RBE and Damage to DNA Linear Energy Transfer (LET) When is stopping power not equal to LET? Stopping power (-de/dx) gives the energy lost by a charged particle in a medium. LET gives the energy absorbed
More informationThe potential role and application of PARP inhibitors in cancer treatment
British Medical Bulletin Advance Access published February 9, 2009 The potential role and application of PARP inhibitors in cancer treatment Anthony J. Chalmers * Genome Damage and Stability Centre, Brighton
More informationProteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival
Supplementary Information for Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival Tatsuro Kawamura 1, Makoto Kawatani 1, Makoto Muroi, Yasumitsu Kondoh,
More informationChapter 2. Aims & Objectives
2.1. Statement of the problem: Earlier reports have shown ambiguous alteration of histone marks in response to DNA damage in asynchronized population of cells. These histone marks not only undergo dynamic
More informationBasics of Radiation Biology
Basics of Radiation Biology Sally A. Amundson Columbia University Center for Radiological Research http://www.cmcr.columbia.edu/ Overview Radiation damage to cells DNA Effects of radiation damage on cells
More informationBasics of Radiation Biology
Basics of Radiation Biology Sally A. Amundson Columbia University Center for Radiological Research http://www.cmcr.columbia.edu/ Overview Radiation damage to cells DNA Effects of radiation damage on cells
More informationResidual gh2ax foci as an indication of lethal DNA lesions
RESEARCH ARTICLE Open Access Residual gh2ax foci as an indication of lethal DNA lesions Judit P Banáth 1, Dmitry Klokov 1,2, Susan H MacPhail 1, C Adriana Banuelos 1, Peggy L Olive 1* Abstract Background:
More informationSUPPLEMENTARY INFORMATION
Supplementary Discussion The cell cycle machinery and the DNA damage response network are highly interconnected and co-regulated in assuring faithful duplication and partition of genetic materials into
More informationHCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation
SUPPLEMENTARY INFORMATION Materials and Methods Human cell lines and culture conditions HCC1937 is the HCC1937-pcDNA3 cell line, which was derived from a breast cancer with a mutation in exon 20 of BRCA1
More informationLegends for Supplemental Figures.
1 Legends for Supplemental Figures. Supplemental Figure 1. Proteasome Inhibition does not abrogate the expression of FA core complex proteins or formation of the FA core complex. (Full-length blots are
More informationSupplementary Information POLO-LIKE KINASE 1 FACILITATES LOSS OF PTEN-INDUCED PROSTATE CANCER FORMATION
Supplementary Information POLO-LIKE KINASE 1 FACILITATES LOSS OF PTEN-INDUCED PROSTATE CANCER FORMATION X. Shawn Liu 1, 3, Bing Song 2, 3, Bennett D. Elzey 3, 4, Timothy L. Ratliff 3, 4, Stephen F. Konieczny
More informationCombined drug and ionizing radiation: biological basis. Prof. Vincent GREGOIRE Université Catholique de Louvain, Cliniques Universitaires St-Luc
Combined drug and ionizing radiation: biological basis Prof. Vincent GREGOIRE Université Catholique de Louvain, Cliniques Universitaires St-Luc Pelvic radiation with concurrent chemotherapy compared with
More informationCancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?
Questions about cancer What is cancer? Cancer Gil McVean, Department of Statistics, Oxford What causes unregulated cell growth? What regulates cell growth? What causes DNA damage? What are the steps in
More informationProlonged mitotic arrest induces a caspase-dependent DNA damage
SUPPLEMENTARY INFORMATION Prolonged mitotic arrest induces a caspase-dependent DNA damage response at telomeres that determines cell survival Karolina O. Hain, Didier J. Colin, Shubhra Rastogi, Lindsey
More informationEffect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa
ONCOLOGY LETTERS 15: 147-154, 2018 Effect of Ku80 on the radiosensitization of cisplatin in the cervical carcinoma cell line HeLa LIANG ZHUANG 1, FEI LIU 1, PING PENG 1, HUIHUA XIONG 1, HONG QIU 1, XIUGEN
More informationResearch Article A Mathematical Model of Tumor Volume Changes during Radiotherapy
The Scientific World Journal Volume 203, Article ID 8070, 5 pages http://dx.doi.org/0.55/203/8070 Research Article A Mathematical Model of Tumor Volume Changes during Radiotherapy Ping Wang and Yuanming
More information(A) SW480, DLD1, RKO and HCT116 cells were treated with DMSO or XAV939 (5 µm)
Supplementary Figure Legends Figure S1. Tankyrase inhibition suppresses cell proliferation in an axin/β-catenin independent manner. (A) SW480, DLD1, RKO and HCT116 cells were treated with DMSO or XAV939
More informationBystander responses and low dose exposure: Current evidence and future research requirements
Bystander responses and low dose exposure: Current evidence and future research requirements Kevin M. Prise Centre for Cancer Research & Cell Biology, Queen s University Belfast Outline Definition of bystander
More informationnuclear science and technology
EUROPEAN COMMISSION nuclear science and technology The role of intercellular communication and DNA double-strand breaks in the induction of bystander effects (INTERSTANDER) Contract N o FIGH-CT2002-00218
More informationLYMHOCYTE CHROMOSOMAL ABERRATION ASSAY IN RADIATION BIODOSIMETRY
LYMHOCYTE CHROMOSOMAL ABERRATION ASSAY IN RADIATION BIODOSIMETRY Dr. Birutė Gricienė 1,2 1 Radiation Protection Centre 2 Vilnius University Introduction Ionising radiation is a well-known mutagenic and
More informationPREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland
AD Award Number: W81XWH-05-1-0494 TITLE: Tumor Suppression by BRCA-1: A Critical Role at DNA Replication Forks PRINCIPAL INVESTIGATOR: Jean Gautier, Ph.D. CONTRACTING ORGANIZATION: Columbia University
More informationSUPPLEMENT. Materials and methods
SUPPLEMENT Materials and methods Cell culture and reagents Cell media and reagents were from Invitrogen unless otherwise indicated. Antibiotics and Tet-certified serum were from Clontech. In experiments
More information"BRCAness," PARP and the Triple-Negative Phenotype
"BRCAness," PARP and the Triple-Negative Phenotype Prof Alan Ashworth, FRS Disclosures for Professor Alan Ashworth, FRS Consulting Agreements GlaxoSmithKline, Pfizer Inc Patent AstraZeneca Pharmaceuticals
More informationHadrons on Malignant Cells: Recent Activities within Collaboration between LNS INFN and Vinca Institute of Nuclear Sciences
ENSAR2 Midterm Meeting of Networking Activity 5: MediNet March 12 th 14 th, 218 Vinča Institute of Nuclear sciences, University of Belgrade Hadrons on Malignant Cells: Recent Activities within Collaboration
More informationRemoval of Shelterin Reveals the Telomere End-Protection Problem
Removal of Shelterin Reveals the Telomere End-Protection Problem DSB Double-Strand Breaks causate da radiazioni stress ossidativo farmaci DSB e CROMATINA Higher-order chromatin packaging is a barrier to
More informationRadiation Oncology. Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology
Radiation Oncology Initial Certification Qualifying (Computer-based) Examination: Study Guide for Radiation and Cancer Biology This exam tests your knowledge of the principles of cancer and radiation biology
More informationSupplementary Figure 1.TRIM33 binds β-catenin in the nucleus. a & b, Co-IP of endogenous TRIM33 with β-catenin in HT-29 cells (a) and HEK 293T cells
Supplementary Figure 1.TRIM33 binds β-catenin in the nucleus. a & b, Co-IP of endogenous TRIM33 with β-catenin in HT-29 cells (a) and HEK 293T cells (b). TRIM33 was immunoprecipitated, and the amount of
More informationNeutron-Energy-Dependent Cell Survival and Oncogenic Transformation
J. RADIAT. RES., 40: SUPPL., 53 59 (1999) Neutron-Energy-Dependent Cell Survival and Oncogenic Transformation RICHARD C. MILLER 1 *, STEPHEN A. MARINO 1, STEWART G. MARTlN 2, KENSHI KOMATSU 3, CHARLES
More information(a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable
Supplementary Figure 1. Frameshift (FS) mutation in UVRAG. (a) Schematic diagram of the FS mutation of UVRAG in exon 8 containing the highly instable A 10 DNA repeat, generating a premature stop codon
More informationInvolvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition
Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition Kenji Sakogawa, 1,2 Yoshiro Aoki, 1,2 Keizo Misumi, 1,2 Yoichi Hamai, 2 Manabu Emi,
More informationResearch Article Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide
SAGE-Hindawi Access to Research Journal of Nucleic Acids Volume 21, Article ID 71589, 8 pages doi:1.461/21/71589 Research Article Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide
More informationCell Damage. Standardized and automatic determination of DNA double strand breaks using immunofluorescence
Standardized and automatic determination of DNA double strand breaks using immunofluorescence Patents: CN 2702421, EP 2208068, TR 201308237, 200880115751 The Platform Motorized, inverse fluorescence microscope
More informationTargeting DNA base excision repair: a new strategy for personalised cancer therapy
GOULSTONIAN LECTURE Clinical Medicine 2012, Vol 12, No 6: s42 s46 Targeting DNA base excision repair: a new strategy for personalised cancer therapy Rachel Abbotts and Srinivasan Madhusudan Introduction
More informationCOMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE
COMPARISON OF RADIOBIOLOGICAL EFFECTS OF CARBON IONS TO PROTONS ON A RESISTANT HUMAN MELANOMA CELL LINE I. Petrovi a, A. Risti -Fira a, L. Kori anac a, J. Požega a, F. Di Rosa b, P. Cirrone b and G. Cuttone
More informationTable S1. New colony formation 7 days after stimulation with doxo and VCR in JURKAT cells
Table S1. New colony formation 7 days after stimulation with and in JURKAT cells drug co + number of colonies 7±14 4±7 48±11 JURKAT cells were stimulated and analyzed as in Table 1. Drug concentrations
More informationTargeted mass spectrometry (LC/MS/MS) for Olaparib pharmacokinetics. For LC/MS/MS of Olaparib pharmacokinetics metabolites were extracted from
Supplementary Methods: Targeted mass spectrometry (LC/MS/MS) for Olaparib pharmacokinetics For LC/MS/MS of Olaparib pharmacokinetics metabolites were extracted from mouse tumor samples and analyzed as
More informationSupplementary Figure 1
Supplementary Figure 1 6 HE-50 HE-116 E-1 HE-108 Supplementary Figure 1. Targeted drug response curves of endometrial cancer cells. Endometrial cancer cell lines were incubated with serial dilutions of
More informationCellometer Image Cytometry for Cell Cycle Analysis
Cellometer Cytometry for Cell Cycle Analysis Importance of Cell Cycle Research Oncology: Since cancer cells often undergo abnormal cell division and proliferation, it is important to understand the cell
More informationTITLE: Novel Mechanisms of PARP inhibitor resistance in BRCA1-deficient Breast Cancers
AWARD NUMBER: W81XWH-13-1-0027 TITLE: Novel Mechanisms of PARP inhibitor resistance in BRCA1-deficient Breast Cancers PRINCIPAL INVESTIGATOR: Stephanie Yazinski CONTRACTING ORGANIZATION: Massachusetts
More informationSupplementary Information. Induction of p53-independent apoptosis by ectopic expression of HOXA5
Supplementary Information Induction of p53-independent apoptosis by ectopic expression of in human liposarcomas Dhong Hyun Lee 1, *, Charles Forscher 1, Dolores Di Vizio 2, 3, and H. Phillip Koeffler 1,
More informationDNA repair pathway choice at various conditions immediately post irradiation
DNA repair pathway choice at various conditions immediately post irradiation Min Liu, Jilin University Hongyan Wang, affiliation Solah Lee, Emory University Bailong Liu, Jilin University Lihua Dong, Jilin
More informationnuclear science and technology
EUROPEAN COMMISSION nuclear science and technology Radiation-specific DNA non-double strand break lesions: repair mechanisms and biological effects (Non-DSB Lesions) Contract N o FIGH-CT2002-00207 Final
More informationDSB. Double-Strand Breaks causate da radiazioni stress ossidativo farmaci
DSB Double-Strand Breaks causate da radiazioni stress ossidativo farmaci METODI DDR foci formation in irradiated (2 Gy) cells fixed 2 h later IRIF IRradiation Induced Focus Laser micro-irradiation DDR
More informationFile Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables. File Name: Peer Review File Description:
File Name: Supplementary Information Description: Supplementary Figures and Supplementary Tables File Name: Peer Review File Description: Primer Name Sequence (5'-3') AT ( C) RT-PCR USP21 F 5'-TTCCCATGGCTCCTTCCACATGAT-3'
More informationOverview and future horizons of PARP inhibitors in BRCAassociated. Judith Balmaña
Overview and future horizons of PARP inhibitors in BRCAassociated breast cancer Judith Balmaña PARP inhibitors: Mechanism of action Clinical development: Monotherapy In combination with chemotherapy Ongoing
More informationRadiation Carcinogenesis
Radiation Carcinogenesis November 11, 2014 Dhyan Chandra, Ph.D. Pharmacology and Therapeutics Roswell Park Cancer Institute Email: dhyan.chandra@roswellpark.org Overview - History of radiation and radiation-induced
More informationThe Role of ATM (ataxia-telangiectasia mutated) in the mitochondrial pathway of apoptosis
The Role of ATM (ataxia-telangiectasia mutated) in the mitochondrial pathway of apoptosis Background Ataxia-Telangiectasia Ataxia-telangiectasia (AT) is a primary immunodeficiency disorder that occurs
More informationRNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using
Supplementary Information Materials and Methods RNA extraction, RT-PCR and real-time PCR. Total RNA were extracted using Trizol reagent (Invitrogen,Carlsbad, CA) according to the manufacturer's instructions.
More informationTumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition
Tumour growth environment modulates Chk1 signalling pathways and sensitivity to Chk1 inhibition Andrew J Massey Supplementary Information Supplementary Figure S1. Related to Fig. 1. (a) HT29 or U2OS cells
More informationMolecular Radiobiology Module 4 Part #3
Molecular Radiobiology Module 4 Part #3 Bushong - Chapter 31 10-526-197 - Rhodes Interaction & damage is a matter of chance Energy deposited rapidly 10-17 seconds Interactions are non-selective in tissue
More informationGenetic Predictors of Radiosensitivity.
Genetic Predictors of Radiosensitivity. Richard G. Stock, MD Professor, Director of Genito-Urinary Oncology Department of Radiation Oncology Ichan School of Medicine at Mount Sinai New York, NY DISCLOSURE
More informationRadiosensitization of cervical cancer cells via double-strand DNA break repair inhibition
Available online at www.sciencedirect.com Gynecologic Oncology 110 (2008) 93 98 www.elsevier.com/locate/ygyno Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition Christa
More informationTargeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer
Targeting DNA repair in BRCA 1/2 and Triple Negative Breast Cancer Andrew Tutt, MB ChB, PhD Consultant Oncologist/Director Breakthrough Breast Cancer Research Unit King s Health Partners Academic Health
More informationAssistant Professor Department of Therapeutic Radiology Yale University School of Medicine
A Mechanism-Based Approach to Predict Relative Biological i Effectiveness and the Effects of Tumor Hypoxia in Charged Particle Radiotherapy David J. Carlson, Ph.D. Assistant Professor Department of Therapeutic
More informationEstimates of Risks LONG-TERM LOW DOSE EFFECTS OF IONIZING RADIATION
Estimates of Risks LONG-TERM LOW DOSE EFFECTS OF IONIZING RADIATION Low Level Radiation Exposure Single exposure of 10 rad or less Larger exposures delivered over periods of days or longer (low dose
More informationAnti-ceramide Antibody Prevents the Radiation GI Syndrome in Mice
Anti-ceramide Antibody Prevents the Radiation GI Syndrome in Mice Jimmy A. Rotolo 1, Branka Stancevic 1, Jianjun Zhang 1, Guoqiang Hua 1, John Fuller 1, Xianglei Yin 1, Adriana Haimovitz-Friedman 2, Kisu
More informationLung cancer is the most common malignancy in both men
ORIGINAL ARTICLE Soy Isoflavones Augment Radiation Effect by Inhibiting APE1/Ref-1 DNA Repair Activity in Non-small Cell Lung Cancer Vinita Singh-Gupta, PhD,* Michael C. Joiner, PhD,* Lindsay Runyan, BSc,*
More informationSupplemental Materials. STK16 regulates actin dynamics to control Golgi organization and cell cycle
Supplemental Materials STK16 regulates actin dynamics to control Golgi organization and cell cycle Juanjuan Liu 1,2,3, Xingxing Yang 1,3, Binhua Li 1, Junjun Wang 1,2, Wenchao Wang 1, Jing Liu 1, Qingsong
More informationFigure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h
Figure S1 Time-dependent down-modulation of HER3 by EZN-392 HE ER3 mrna A, %Contr rol 12 No Treatment EZN-392, 2 μm 1 8 6 4 2 2 8 24 Time, h Figure S2. Specific target down-modulation by HER3 (EZN-392)
More informationEvidence for variation in human radiosensitivity: potential impact on radiological protection
Evidence for variation in human radiosensitivity: potential impact on radiological protection Simon Bouffler 22 October 2015 ICRP Symposium 2015, Seoul, South Korea Current system of protection Avoid tissue
More informationThe range of radiosensitivity in the human population: hyper- and hypo-sensitivity
International Conference on Modern Radiotherapy The range of radiosensitivity in the human population: hyper- and hypo-sensitivity Simon Bouffler December 2009 Indicators of radiosenitivity In Patients
More informationERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2
ERK1/2/MAPK pathway-dependent regulation of the telomeric factor TRF2 SUPPLEMENTARY FIGURES AND TABLE Supplementary Figure S1: Conservation of the D domain throughout evolution. Alignment of TRF2 sequences
More informationLOW DOSES OF RADIATION REDUCE RISK IN VIVO
Dose-Response: An International Journal Volume 5 Issue 1 ADAPTIVE BIOLOGICAL RESPONSES FOLLOWING EXPOSURES TO IONIZING RADIATION Article 4 3-2007 LOW DOSES OF RADIATION REDUCE RISK IN VIVO REJ Mitchel
More informationUse of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation.
Radiation Therapy Use of radiation to kill diseased cells. Cancer is the disease that is almost always treated when using radiation. One person in three will develop some form of cancer in their lifetime.
More informationSupporting Information
Supporting Information Toller et al. 10.1073/pnas.1100959108 SI Materials and Methods Cell Lines, Bacterial Strains, and Infection Conditions. Cell lines were grown in the following media: AGS, U2OS, stable
More information[Abstract] Objective: Investigate the effect of KLT on the expression of Fas/Apo-1, FasL and PCNA genes in renal carcinoma cell line (GRC-1).
Study on Effect of Kanglaite Injection(KLT) on the Expression of Fas/Apo-1, FasL and PCNA in Renal Carcinoma Cell Lines Wang Junjie, Sun Xinchen, Sheng Wenjiang, Yu Lizhang [Abstract] Objective: Investigate
More informationThe MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.
O[superscript 6]-Methylguanine DNA lesions induce an intra-s-phase arrest from which cells exit into apoptosis governed by early and late multi-pathway signaling The MIT Faculty has made this article openly
More informationEffective Suppression of Bystander Effects by DMSO Treatment of Irradiated CHO Cells
J. Radiat. Res., 48, 327 333 (2007) Regular Paper Effective Suppression of Bystander Effects by DMSO Treatment of Irradiated CHO Cells Genro KASHINO 1 *, Kevin M PRISE 2,3, Keiji SUZUKI 4, Naoki MATSUDA
More informationHealth Physics and the Linear No-Threshold Model
Health Physics and the Linear No-Threshold Model Understanding Radiation and Its Effects John Baunach Vanderbilt University Nashville, TN What is health physics? Outline What organizational bodies govern
More informationRadiobiological Effects of Alpha-Particles from Astatine-211
Radiobiological Effects of Alpha-Particles from Astatine-211 From DNA Damage to Cell Death Kristina Claesson Department of Oncology Institute of Clinical Sciences The Sahlgrenska Academy at University
More informationCancer Drug Discovery and Development. Philip J. Tofilon Kevin Camphausen Editors. Increasing the Therapeutic Ratio of Radiotherapy
Cancer Drug Discovery and Development Philip J. Tofilon Kevin Camphausen Editors Increasing the Therapeutic Ratio of Radiotherapy Cancer Drug Discovery and Development Series Editor Beverly A. Teicher
More informationDako IT S ABOUT TIME. Interpretation Guide. Agilent Pathology Solutions. ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis)
INTERPRETATION Dako Agilent Pathology Solutions IQFISH Interpretation Guide ALK, ROS1 and RET IQFISH probes (Dako Omnis) MET IQFISH probe (Dako Omnis) IT S ABOUT TIME For In Vitro Diagnostic Use ALK, ROS1,
More informationTOUR REPORT. Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad
TOUR REPORT Report on participation of the ICMR International Fellow (ICMR IF) in Training / Research abroad 1. Name and Designation of ICMR IF : Dr. A. Venkateshwari, Assistant Professor 2. Address: Dr.
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationNon-classical radiobiology relevant to high-doses per fraction
Non-classical radiobiology relevant to high-doses per fraction Michael Joiner Wayne State University Radiation Oncology Detroit, Michigan joinerm@wayne.edu Why reconsider high dose fractions? Because we
More informationPrecision Therapeutics For Hard-To-Treat Cancers
Precision Therapeutics For Hard-To-Treat Cancers George O. Elston, CEO Life Sciences Summit November 2, 2017 1 About Us Precision therapeutics addressing significant unmet medical needs in hard-to-treat
More informationLankenau Institute for Medical Research Annual Progress Report: 2011 Formula Grant
Lankenau Institute for Medical Research nnual Progress Report: 2011 Formula Grant Reporting Period July 1, 2012 December 31, 2012 Formula Grant Overview The Lankenau Institute for Medical Research received
More informationSupporting Information. FADD regulates NF-кB activation and promotes ubiquitination of cflip L to induce. apoptosis
1 2 Supporting Information 3 4 5 FADD regulates NF-кB activation and promotes ubiquitination of cflip L to induce apoptosis 6 7 Kishu Ranjan and Chandramani Pathak* 8 9 Department of Cell Biology, School
More information